An additional novel dual-target inhibitor of RSK1/MSK2, APIO-EE-07, is used against colon cancer and inhibits cell proliferation through the downregulation of ATF1 expression and increased expression of Bax, caspase-3, and PARP. Here, RPS6KA1 is linked to colonic neoplasm.